FIELD: medicine; allergology; dermatology.
SUBSTANCE: group of inventions discloses a method of treatment of atopic dermatitis including the administration of an IL-31 antagonist several times in equal quantities at equal intervals between the doses to a subject suffering from atopic dermatitis or predisposed to its development, at a dose of 25 to 100 mg/body/4 weeks, where atopic dermatitis is moderate to severe atopic dermatitis and topical therapy is insufficiently effective or intolerable (options).
EFFECT: use of a group of inventions ensures an increase in the effectiveness of the treatment regimen, the results of which cannot be achieved using standard therapeutic methods of treating atopic dermatitis.
12 cl, 4 tbl, 11 dwg, 6 ex
Title |
Year |
Author |
Number |
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS, INCLUDING IL-31 ANTAGONIST AS THE ACTIVE INGREDIENT |
2016 |
- Kaneko Akikhisa
- Ivayanagi Yuki
- Kitamura Khidetomo
- Khiguti Josinobu
- Matsusita Khiroaki
- Mikhara Resuke
- Yamamoto Yumi
- Saito Tomokhisa
- Khirokava Kejko
|
RU2749512C2 |
TREATMENT OF SKIN LESIONS AND ITCHING IN PATIENTS WITH PRURIGO NODOSUM |
2020 |
|
RU2822134C2 |
METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST |
2017 |
- Purcell Ngambo, Lisa
- Graham, Neil
- Murphy, Andrew J.
- Evans, Robert
|
RU2753869C2 |
PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII |
2015 |
|
RU2721910C2 |
PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS |
2023 |
- Shukurov Rakhim Rakhmankulyevich
- Reshetnik Elizaveta Vyacheslavovna
- Khamitov Ravil Avgatovich
- Shuster Aleksandr Mikhajlovich
|
RU2814280C1 |
METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST |
2017 |
- Hamilton, Jennifer D.
- Swanson, Brian N.
|
RU2777328C2 |
USE OF ANTIBODIES TO SCLEROSTIN FOR TREATING OSTEOGENESIS IMPERFECTA |
2017 |
- Yunker, Uve
- Knejssel, Mikhaela
- Kholl, Entoni Kent
- Eudi, Rena Dzhoj
- Riggs, Mettyu Menning
|
RU2789033C2 |
NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS |
2015 |
- Andre Paskal
- Bleri Mate
- Paturel Karin
- Vagtmann Nikolaj
|
RU2734771C2 |
PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY |
2008 |
- Shreter Salli
- Gejms Kejt Dora
|
RU2523894C2 |
METHOD OF TREATMENT OF ATOPIC DERMATITIS THROUGH INTRODUCTION OF IL-4R INHIBITOR |
2019 |
|
RU2801204C2 |